GET DAILY SIGNALSWhy Is TriSalus Life Sciences (TLSI) Stock Down -22.98% Today?
Key Takeaways
- Move: TLSI shares fell 22.98% to $2.48 in early trading Tuesday, down $0.74 from Monday's $3.22 close, after touching an intraday low of $2.36.
- Primary catalyst: Third-quarter revenue of $12.88 million missed the roughly $14.3 million consensus, and management slashed full-year 2026 revenue guidance to $46 million–$48 million from $54 million–$57 million.
- Secondary drivers: A wider-than-expected loss per share of $0.15 and an acknowledgment that the expanded commercial team ramped more slowly than planned.
- Context: The selloff unfolded against a mildly risk-off tape, with small caps and biotech modestly lower, though nothing sector-wide accounts for a 23% decline.
- News Significance Score: 82/100 — Major guidance reset paired with an extreme, rare decline of roughly eight times the stock's typical daily move.
- What to watch: Fourth-quarter revenue trajectory, 2027 Medicare reimbursement, TriNav Advance adoption and the company's cash runway.
- For deeper research, explore Price Targets, Earnings and Forecast pages on Tickeron.
- Also worth reviewing: Trending AI Robots, Tickeron's curated list of top-performing automated strategies.
Session Overview
TriSalus Life Sciences, Inc. (TLSI) is a Westminster, Colorado-based oncology-focused medical technology company whose TriNav Infusion System uses Pressure-Enabled Drug Delivery to improve the delivery of standard-of-care therapies into liver and pancreatic tumors. Its shares fell 22.98% to $2.48 in Tuesday's early session, compared with the prior close of $3.22, marking the steepest single-session decline since May. The stock opened at $2.56 and slid as low as $2.36 before stabilizing slightly. The catalyst was unambiguous: a third-quarter revenue miss combined with a sharp reduction in full-year revenue guidance, both published before the opening bell.
Third-Quarter Results Miss Consensus
Revenue rose 11.3% year over year to $12.88 million from $11.57 million, but landed well short of the approximately $14.3 million analysts had modeled. The GAAP net loss narrowed to $8.85 million from $10.81 million, and the loss per share of $0.15 came in above the roughly $0.12–$0.13 consensus.
The underlying operating picture was mixed rather than disastrous. Gross margin improved to 86.2% from 83.5% on lower TriNav unit costs, research and development expense fell 44.1% to $3.19 million, and general and administrative costs dropped 20.4%. Those savings were partly offset by sales and marketing spending that jumped 56.9% to $10.73 million as the company absorbed the cost of a much larger field force. Adjusted EBITDA losses narrowed to $4.7 million from $5.4 million.
2026 Guidance Cut Resets Growth Expectations
The decisive driver was the outlook. TriSalus cut its full-year 2026 revenue guidance to $46 million–$48 million, implying growth of just 2% to 6%, from a prior range of $54 million–$57 million that had targeted 19% to 26% growth. The new midpoint sits roughly 11% below the $53.1 million consensus and represents a reduction of about 15% against the company's own prior midpoint.
Management attributed the reset to slower-than-expected productivity from the sales force it doubled earlier in the year, with executives conceding on the morning call that the pace of the ramp had been overestimated. For a company with a market capitalization near $150 million and a single dominant product line, that kind of guidance reset forces a full re-basing of near-term revenue models — which is precisely what the price action reflected.
Cash Position and a 2027 Offset
The quarter was not without offsets. Cash and equivalents stood at $41.1 million on September 30, up from $20.4 million at the end of 2025 following a February equity raise, giving the company room to fund operations. TriSalus also noted that the Centers for Medicare & Medicaid Services finalized expanded reimbursement for PEDD procedures effective January 2027 — a genuine tailwind, but one that does nothing for 2026 numbers.
Market Context and Trading Activity
Volume was heavy. More than 130,000 shares changed hands in the first fifteen minutes of regular trading, close to a typical full session's turnover of roughly 150,000 to 175,000 shares, and the stock traded on a lower opening gap that widened through the first hour.
The broader tape offered no cover. Small caps, measured by the Russell 2000 proxy, were down about 1.1%, the Nasdaq-100 was off roughly 0.9%, and a broad biotech ETF was lower by about 0.8%. The divergence between a sub-1% index drift and a 23% single-stock collapse confirms the move was company-specific.
Technically, the decline broke the $3.20–$3.25 floor that had held since early November and left the shares far below their 50-day and 200-day moving averages, both of which sit above $4.25. The next reference point is the 52-week low of $2.20, set in May.
News Significance Score
On a scale where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news and an extreme, rare price move, TLSI scores 82 out of 100.
The verified news was substantial relative to the company's size: a double-digit percentage cut to full-year revenue guidance, a quarterly revenue shortfall of roughly 10%, and an explicit admission that internal ramp assumptions were too optimistic. The price response was equally extreme. At 22.98%, the decline was about eight times the stock's average absolute daily move of roughly 2.7% over the past 80 sessions, and no session in that window came within seven percentage points of it. Strong fundamental news combined with a historically rare move produces the high score.
What Comes Next for TLSI
Attention now shifts to fourth-quarter execution. The lowered guidance implies $12.8 million to $14.8 million of revenue in the December quarter, so the sequential trajectory will be scrutinized closely, along with whether sales-and-marketing spend finally begins to moderate. The January 2027 expansion of Medicare reimbursement remains the most tangible medium-term catalyst, and progress on TriNav Advance adoption will determine whether the commercial build-out pays off. Analyst estimate revisions are likely in the coming days, and the company's cash runway, product concentration and potential dilution risk remain the central uncertainties. Investors should also watch for any change in churn among institutional holders following the reset.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the page is a practical starting point for comparing live approaches side by side. For readers tracking volatile names like this one, reviewing the current leaders is a simple way to see which automated strategies are adapting best to present conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TLSI's Indicator enters downward trend
The Aroon Indicator for TLSI entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator formed such a pattern. In 139 of the 165 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLSI as a result. In 55 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for TLSI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 33 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
The 50-day moving average for TLSI moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLSI's RSI Indicator exited the oversold zone, 21 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +8.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSI advanced for three days, in 136 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
TLSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TLSI's P/B Ratio (30.552) is slightly higher than the industry average of (4.142). P/E Ratio (-2.444) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.459) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. TLSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement